Loading organizations...
§ Private Profile · 9540 Towne Centre Dr Ste 100, San Diego, California, 92121, United States
Biotechnology company developing nanotechnology systems for genome analysis in life sciences, focused on single-molecule analysis.
Bionano Genomics develops nanotechnology-based systems for genome analysis that provide long-range structural views to complement or replace traditional sequencing methods for life sciences applications. Operating as a publicly traded entity, the enterprise has secured over $450 million through various debt and equity financing rounds since completing its initial public offering in October 2018. The firm's proprietary nanoAnalyzer systems facilitate advanced single-molecule analysis for complex applications across the biotechnology and healthcare sectors, primarily serving institutional research laboratories and commercial diagnostic companies. The organization's core technology originally emerged from academic research conducted at Princeton University, and its current executive leadership team includes Chief Executive Officer Erik Holmlin alongside Board Chairman Albert Luderer. Corporate financial operations and regulatory compliance standards have been historically guided by senior finance executives such as Mark Oldakowski. The biotechnology company was founded by researcher Han Cao.
Bionano Genomics has raised $148.8M across 8 funding rounds.
Bionano Genomics has raised $148.8M in total across 8 funding rounds.
Bionano Genomics has raised $148.8M in total across 8 funding rounds.
Bionano Genomics's investors include Domain Associates, Questa Capital, Darren Cai, Campbell Murray, Battelle Ventures, Federated Kaufmann Fund, Gund Investment Corporation, Monashee Investment Management, Gund Investment, Innovation Valley Partners, KT Venture Group, National Human Genome Research Institute.
Bionano Genomics has raised $148.8M across 8 funding rounds. Most recently, it raised $32.0M Series D in July 2016.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jul 1, 2016 | $32M Series D | — | Domain Associates, Questa Capital | Announced |
| Feb 1, 2016 | $10M Series D | — | Domain Associates, Questa Capital | Announced |
| Nov 1, 2014 | $53M Series C | Darren CAI, Campbell Murray | Domain Associates, Questa Capital, Battelle Ventures, Federated Kaufmann Fund, Gund Investment Corporation, Monashee Investment Management | Announced |
| Oct 2, 2013 | $10M Venture Round | — | Battelle Ventures, Domain Associates, Gund Investment Corporation | Announced |
| Oct 1, 2013 | $10M Series C | — | Domain Associates, Questa Capital, Battelle Ventures, Gund Investment Corporation | Announced |
| Jul 1, 2012 | $10M Series B | — | Domain Associates, Questa Capital, Battelle Ventures, Gund Investment | Announced |
| Mar 1, 2011 | $23M Series B | Domain Associates | Questa Capital, Battelle Ventures, Gund Investment Corporation, Innovation Valley Partners, KT Venture Group | Announced |
| Oct 15, 2009 | $830K Grant | National Human Genome Research Institute | — | Announced |
Bionano Genomics is a biotechnology company specializing in optical genome mapping (OGM) technology to provide advanced genomic analysis tools for researchers and clinicians.[1][2][3][6] Its flagship products, including the Saphyr and Stratys systems, enable high-resolution detection of structural variations in genomes—such as insertions, deletions, and translocations—that traditional methods like short-read sequencing often miss, serving academic institutions, pharmaceutical companies, clinical labs, and diagnostic services in areas like oncology, rare diseases, reproductive health, and neurodevelopmental disorders.[1][2][3] The company solves key problems in genomic research and diagnostics by delivering comprehensive, scalable genome maps that accelerate discoveries in precision medicine, improve patient outcomes, and streamline lab workflows, with growth driven by expanding OGM adoption, software enhancements like EnFocus and VIA, strategic partnerships (e.g., Revvity), and clinical service integrations.[2][3][4]
Bionano Genomics emerged from innovations in genome imaging technology, with its clinical testing roots tracing back to Lineagen, founded in 2006 through collaborations with leading autism research centers like the University of Utah and Children’s Hospital of Philadelphia (CHOP).[4][5] Lineagen pioneered structural variation detection for pediatric neurodevelopmental disorders, including autism spectrum disorder (ASD) and developmental delay, developing proprietary assays like FirstStepDx Plus that combined cytogenetics, software, and databases.[4][5] In a pivotal acquisition, Lineagen joined Bionano, integrating its CLIA-certified diagnostic services and expertise in commercialization, genetic counseling, and reimbursement with Bionano's Saphyr platform, which outperforms traditional karyotyping, chromosomal microarray (CMA), and FISH.[4] This merger, highlighted by Michael Paul, PhD (former Lineagen CEO and Bionano Chief Strategy Officer), accelerated innovation in OGM-based tests, expanding from research to clinical applications globally via facilities like a new CLIA/CAP-certified lab in San Diego.[4][5]
Bionano stands out in genomic analysis through its proprietary OGM technology, which visualizes ultra-long DNA molecules for a macro-level genome view, detecting all classes of structural variants with higher resolution and comprehensiveness than sequencing or cytogenetics alone.[1][2][3]
Bionano rides the explosive growth in genomics and precision medicine, where demand for structural variant detection surges amid rising cancer, rare disease, and neurodevelopmental cases, fueled by market forces like falling sequencing costs and regulatory pushes for advanced diagnostics.[1][2][6] Its OGM fills a critical gap in the "genome visualization" trend, complementing base-pair-focused sequencers by providing holistic structural insights essential for personalized therapies and ending "diagnostic odysseys."[3][6] Timing aligns with biotech's shift to multi-omics integration, where Bionano influences the ecosystem by standardizing OGM in workflows, partnering with pharma and labs, and driving clinical adoption—positioning it as a key enabler in oncology, reproductive health, and cell/gene therapy amid a projected genomics market boom.[2][3][4]
Bionano is poised to dominate OGM as clinical adoption accelerates, with next steps focusing on software expansions (e.g., VIA for multi-tech integration), new LDTs via Bionano Laboratories, and global partnerships to secure reimbursement and scale flowcell sales.[2][3][4] Trends like AI-driven bioinformatics, rising precision oncology demands, and cell therapy QC will propel growth, potentially evolving its influence from niche innovator to genome analysis standard-bearer.[1][2][6] As it transforms how the world sees the genome, Bionano's tech edge promises to unlock actionable insights, empowering earlier diagnoses and therapies in an era of genomic breakthroughs.[3][6]